Naoki Takamatsu, Hiroki Kimura, Mari S Oba, H. Chiba, Ikue Umemoto, Y. Moriyama, Nobuaki Matsunaga, S. Morioka, Daisuke Mori, Kazuhiro Hara, A. Ogura, K. Yoshida, Hirohisa Watanabe, S. Maesawa, Masashi Ikeda, M. Katsuno, N. Ohmagari, M. Takao, Shinsuke Kito, Norio Ozaki, Hironori Kuga
2026.2.27Neuropsychopharmacology Reports
tlooto Summary
This study aimed to characterize the temporal profile of inflammatory markers, particularly interleukin (IL)‐1β, in post‐COVID‐19 patients compared with pre‐pandemic healthy controls, using data from the Psychiatric Symptoms for COVID‐19 Registry Japan (PSCORE‐J).
Abstract
COVID‐19 has been associated with dysregulated immune responses, with increasing evidence indicating sustained inflammasome activation and subsequent pro‐inflammatory cytokine production. This study aimed to characterize the temporal profile of inflammatory markers, particularly interleukin (IL)‐1β, in post‐COVID‐19 patients compared with pre‐pandemic healthy controls, using data from the Psychiatric Symptoms for COVID‐19 Registry Japan (PSCORE‐J).
Citation format
TAKAMATSU, Naoki, et al. Persistent interleukin‐1β elevation in post‐covid‐19 patients: Findings from a nationwide registry study in Japan. Neuropsychopharmacology Reports, 2026, 46(1): e70082.